Pharsight

1. Aggrastat patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770660	MEDICURE	Method for inhibiting platelet aggregation	May, 2023 (4 months ago)

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 May, 1998

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...

Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
12.5 mg/250 mL	03 Oct, 2018	1	08 Apr, 2021	01 May, 2023	Extinguished Non-Forfeiture Deferred
5 mg/100 mL	29 Aug, 2019	1	07 Feb, 2023	01 May, 2023	Extinguished Deferred

Strength	Dosage	Availability
EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	INJECTABLE;INJECTION	Discontinued
EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	SOLUTION;INJECTION	Prescription

AGGRASTAT family patents

2. Zypitamag patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829186	MEDICURE	Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof	Jan, 2031 (7 years from now)